Macrophage-targeted Isoniazid-selenium nanoparticles promote innate immunity, inducing synergistic antimicrobial and bactericidal destructions of tuberculosis bacilli.
Pathogenesis hallmarks for tuberculosis (TB) are the mycobacterium tuberculosis (Mtb) escape from phagolysosomal destruction and limited drug delivery into host cells. Several nanomaterials can entrap into lysosomes, but how to develop functional nanomaterials to promote phagolysosomal Mtb clearance remains a big challenge. Here, we first reported the bactericidal effects of selenium nanoparticles (Se NPs) against Mtb and further introduced a novel nanomaterial-assisted anti-TB strategy manipulating Ison@Man-Se NPs for synergistic drug killing and phagolysosomal destructions of Mtb. Ison@Man-Se NPs preferentially entered macrophages and accumulated in lysosomes releasing Isoniazid. And surprisingly, Ison@Man-Se/Man-Se NPs further promoted the fusion of Mtb into lysosomes for synergistic lysosomal and Isoniazid destructions of Mtb. Concurrently, Ison@Man-Se/Man-Se NPs also induced autophagy sequestration of Mtb, evolving into lysosome-associated autophagosomal Mtb degradation linked to ROS-mitochondrial and PI3K/Akt/mTOR signaling pathway. This novel nanomaterial-assisted anti-TB strategy manipulating antimicrobial immunity may potentially serve as more effective therapeutics against TB and drug-resistant TB.